CTNM Strangle Strategy

CTNM (Contineum Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

CTNM (Contineum Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $530.5M, a beta of 0.89 versus the broader market, a 52-week range of 3.72-16.33, average daily share volume of 292K, a public-listing history dating back to 2024, approximately 51 full-time employees. These structural characteristics shape how CTNM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.89 places CTNM roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on CTNM?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current CTNM snapshot

As of June 29, 2026, spot at $15.23, ATM IV 176.10%, IV rank 22.99%, expected move 50.49%. The strangle on CTNM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.

Why this strangle structure on CTNM specifically: CTNM IV at 176.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a CTNM strangle, with a market-implied 1-standard-deviation move of approximately 50.49% (roughly $7.69 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CTNM expiries trade a higher absolute premium for lower per-day decay. Position sizing on CTNM should anchor to the underlying notional of $15.23 per share and to the trader's directional view on CTNM stock.

CTNM strangle setup

The CTNM strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CTNM near $15.23, the first option leg uses a $15.99 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CTNM chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CTNM shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$15.99	N/A
Buy 1	Put	$14.47	N/A

CTNM strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

CTNM strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on CTNM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on CTNM

Strangles on CTNM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTNM chain.

CTNM thesis for this strangle

The market-implied 1-standard-deviation range for CTNM extends from approximately $7.54 on the downside to $22.92 on the upside. A CTNM long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CTNM IV rank near 22.99% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CTNM at 176.10%. As a Healthcare name, CTNM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CTNM-specific events.

CTNM strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CTNM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CTNM alongside the broader basket even when CTNM-specific fundamentals are unchanged. Always rebuild the position from current CTNM chain quotes before placing a trade.

Frequently asked questions

What is a strangle on CTNM?: A strangle on CTNM is the strangle strategy applied to CTNM (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CTNM stock trading near $15.23, the strikes shown on this page are snapped to the nearest listed CTNM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are CTNM strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CTNM strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 176.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CTNM strangle?: The breakeven for the CTNM strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CTNM market-implied 1-standard-deviation expected move is approximately 50.49%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on CTNM?: Strangles on CTNM are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CTNM chain.
How does current CTNM implied volatility affect this strangle?: CTNM ATM IV is at 176.10% with IV rank near 22.99%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.